Clinical benefit associated with biomarker changes indicative of disease modification in patients with myelofibrosis treated with the BET inhibitor pelabresib as monotherapy or in combination with ruxolitinib Meeting Abstract
| Authors: | Scandura, J.; Verstovsek, S.; Kremyanskaya, M.; Talpaz, M.; Rampal, R. K.; Vannucchi, A.; Gupta, V.; Palandri, F.; Patriarca, A.; Bose, P.; Chen, D.; Zavidij, O.; Cui, J. K.; Chang, T. W.; Taverna, P.; Mascarenhas, J.; Harrison, C. |
| Abstract Title: | Clinical benefit associated with biomarker changes indicative of disease modification in patients with myelofibrosis treated with the BET inhibitor pelabresib as monotherapy or in combination with ruxolitinib |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 1523 |
| End Page: | 1525 |
| Language: | English |
| ACCESSION: | WOS:000893223201216 |
| DOI: | 10.1182/blood-2022-159409 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
